Huge article on how NAFLD is an independent risk factor for cardiac disease.
Find it on Yahoo.
This is big. It means, unrelated to cirrhosis and its complications, you are a set up for cardiac events with NASH.
This expands the patient pool for NASH drugs to 1/2 the population.
Agree with you. Timing, around tax time, seems right. They probably just had to raise some money.
the clown, spree nonsense.
despose of 44,000 shares ?
Maybe to suppress the price from going higher ??????????
Pan caspase inhibitor has no effect on tumor cell growth or therapy with Nexavar. That is good. and it was one of my major concerns in using that drug.
However, if one considers the entire pathway whereby the HSC cell becomes activated to a myofiblast and then lays down collagen I still believe that complete disruption of cell to cell signaling via Gal 3 binding is a better play.
Time will tell.
Especially in a day and age where secrets are impossible to keep. Scenario for illustration purposes only -- A lab tech, or an XRAY tech sees some change on a Fibroscan or an MR elastography and puts two and two together.
Word spreads quickly. Not saying this happened, but scenarios such as above are plausible.
so sorry GALT is upsetting your day, jsm and your alter ego "thumbs down" guy.
That was quick ! Lets see how quick I can get two thumbs down, gonna clock it
Burn rate is the major problem that I see. Looks like another secondary will be coming. They will need good results in September to allow the stock to drift to 4-6 dollar range and then dilute.
I think that's the game plan.
FX keeps them in business, and then CX blows them out of the water to be bought out at a nice multiple- probably at a 2.5 - 3 billion valuation. That's the way I see things.